Monday, December 23, 2024
HomeTagsTARRYTOWN

TARRYTOWN

CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics